Elizabeth A David1, David T Cooke2, Yingjia Chen3, Andrew Perry2, Robert J Canter4, Rosemary Cress5. 1. Section of General Thoracic Surgery, Department of Surgery, UC Davis Medical Center, Sacramento, CA, USA; Heart Lung Vascular Center, David Grant Medical Center, Travis Air Force Base, CA, USA. Electronic address: Elizabeth.david@ucdmc.ucdavis.edu. 2. Section of General Thoracic Surgery, Department of Surgery, UC Davis Medical Center, Sacramento, CA, USA. 3. Department of Public Health Sciences, UC Davis Medical Center, Sacramento, CA, USA. 4. Division of Surgical Oncology, Department of Surgery, UC Davis Medical Center, Sacramento, CA, USA. 5. Department of Public Health Sciences, UC Davis Medical Center, Sacramento, CA, USA; Public Health Institute, Cancer Registry of Greater California, Sacramento, CA, USA.
Abstract
BACKGROUND: Quality of oncologic outcomes is of paramount importance in the care of patients with non-small cell lung cancer (NSCLC). We sought to evaluate the relationship of hospital volume for lobectomy on cancer-specific survival in NSCLC patients treated in California, as well as the influence of Commission on Cancer (CoC) accreditation. METHODS: The California Cancer Registry was queried from 2004 to 2011 for cases of Stage I NSCLC and 8,345 patients were identified. Statistical analysis was used to determine prognostic factors for cancer-specific survival. RESULTS: A total of 7,587 patients were treated surgically. CoC accreditation was not significant for cancer-specific survival, but treatment in high-volume centers was associated with longer survival when compared with low- and medium-volume centers (hazard ratio 1.77, 1.474 to 2.141 and hazard ratio 1.23, 1.058 to 1.438). CONCLUSION: These data suggest that surgical treatment in high-volume hospitals is associated with longer cancer-specific survival for early-stage NSCLC, but that CoC accreditation is not. Published by Elsevier Inc.
BACKGROUND: Quality of oncologic outcomes is of paramount importance in the care of patients with non-small cell lung cancer (NSCLC). We sought to evaluate the relationship of hospital volume for lobectomy on cancer-specific survival in NSCLC patients treated in California, as well as the influence of Commission on Cancer (CoC) accreditation. METHODS: The California Cancer Registry was queried from 2004 to 2011 for cases of Stage I NSCLC and 8,345 patients were identified. Statistical analysis was used to determine prognostic factors for cancer-specific survival. RESULTS: A total of 7,587 patients were treated surgically. CoC accreditation was not significant for cancer-specific survival, but treatment in high-volume centers was associated with longer survival when compared with low- and medium-volume centers (hazard ratio 1.77, 1.474 to 2.141 and hazard ratio 1.23, 1.058 to 1.438). CONCLUSION: These data suggest that surgical treatment in high-volume hospitals is associated with longer cancer-specific survival for early-stage NSCLC, but that CoC accreditation is not. Published by Elsevier Inc.
Entities:
Keywords:
Cancer-specific survival; Commission on cancer accreditation; Lobectomy; Non–small cell lung cancer; Sublobar resection; Thoracic surgery
Authors: Margreet Lüchtenborg; Sharma P Riaz; Victoria H Coupland; Eric Lim; Erik Jakobsen; Mark Krasnik; Richard Page; Michael J Lind; Michael D Peake; Henrik Møller Journal: J Clin Oncol Date: 2013-07-29 Impact factor: 44.544
Authors: M W J M Wouters; S Siesling; M L Jansen-Landheer; M A G Elferink; J Belderbos; J W Coebergh; F M N H Schramel Journal: Eur J Surg Oncol Date: 2010-07-03 Impact factor: 4.424
Authors: Benjamin D Kozower; Shubin Sheng; Sean M O'Brien; Michael J Liptay; Christine L Lau; David R Jones; David M Shahian; Cameron D Wright Journal: Ann Thorac Surg Date: 2010-09 Impact factor: 4.330
Authors: David A Etzioni; Tonia M Young-Fadok; Robert R Cima; Nabil Wasif; Robert D Madoff; James M Naessens; Elizabeth B Habermann Journal: Cancer Date: 2014-05-06 Impact factor: 6.860
Authors: Karl Y Bilimoria; David J Bentrem; Andrew K Stewart; David P Winchester; Clifford Y Ko Journal: J Clin Oncol Date: 2009-07-27 Impact factor: 44.544
Authors: Dylan T Wolff; Thomas F Monaghan; Danielle J Gordon; Kyle P Michelson; Tashzna Jones; Raymond Khargi; Matthew T Smith; Fenizia Maffucci; Hyezo Kwun; Nicholas R Suss; Andrew G Winer Journal: Medicina (Kaunas) Date: 2021-06-29 Impact factor: 2.430